Ramana Kolady
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ramana Kolady has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Ganesh M. Babulal
Department of Neurology Mayo Clinic Rochester Minnesota USA
2 shared publications Afshin E. Razi
1 shared publicationAlan S. Hilibrand
1 shared publication- Alexander Richard Vaccaro
Rothman Orthopaedic Institute, Thomas Jefferson University, Philadelphia, USA
1 shared publication - Amaar Alwani1 shared publication
Amanda Dias
School of Social Work, Adelphi University, Garden City, NY, USA
1 shared publication
Latest Publications
- 2 September 2026
- Published by Elsevier in The Spine Journal
- Vol. 26 (12) , 2336-2350
Longitudinal trends in US Medicare physician reimbursement for common lumbar spine surgery CPT codes: a systematic review
- 2 September 2026
- Published by Elsevier in The Spine Journal
- Vol. 26 (12) , 2336-2350
Longitudinal trends in US Medicare physician reimbursement for common lumbar spine surgery CPT codes: a systematic review
- 21 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 3-14
The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review
Background: As the fastest-growing segment of the population, adults over 65 are at the most significant risk for Alzheimer's disease (AD). Older adults often use anti-seizure medications (ASMs), which can negatively impact cognitive function, mood, and behavior, mimicking AD or its symptoms. Understanding the effects of ASMs across diverse older adults is crucial, given that some ethnoracial groups are at higher risk for AD or more severe symptoms compared to non-Hispanic Whites. Objective: To summarize the current evidence on the association of ASMs with AD risk and AD-related symptoms and explore the inclusion of ethnoracial minority groups in these studies. Methods: Data sources included PubMed/MEDLINE, EMBASE, and SCOPUS for English-language studies published between 1990–2024. Selected studies were peer-reviewed, cross-sectional, longitudinal, case-control, and clinical trials on AD dementia or related symptoms and ASMs. Study quality was rated by the Oxford Centre for Evidence-Based Research Medicine. Results: A total of 27 studies with 1,241,796 participants were included. Data on AD risk from level IB-IIIB evidence studies showed mixed results, with some indicating an increased association with ASM use [OR = 1.05–1.16, 95% CI: 1.01–1.24]. Studies on AD-related symptoms from level IB-IV evidence also showed mixed results. Only three North American studies explicitly included race/ethnicity; most were conducted in European countries. Conclusions: ASM use may be modestly associated with an increased risk of AD among the older adult population, but current data are inconclusive. The association of ASMs on AD-related symptoms varied. Future studies should emphasize reporting sociodemographic data and include diverse cohorts to enhance the applicability of findings.
- 21 March 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 105 (1) , 3-14
The effect of anti-seizure medications on Alzheimer's disease (AD) risk and AD-related symptoms: A scoping review
Background: As the fastest-growing segment of the population, adults over 65 are at the most significant risk for Alzheimer's disease (AD). Older adults often use anti-seizure medications (ASMs), which can negatively impact cognitive function, mood, and behavior, mimicking AD or its symptoms. Understanding the effects of ASMs across diverse older adults is crucial, given that some ethnoracial groups are at higher risk for AD or more severe symptoms compared to non-Hispanic Whites. Objective: To summarize the current evidence on the association of ASMs with AD risk and AD-related symptoms and explore the inclusion of ethnoracial minority groups in these studies. Methods: Data sources included PubMed/MEDLINE, EMBASE, and SCOPUS for English-language studies published between 1990–2024. Selected studies were peer-reviewed, cross-sectional, longitudinal, case-control, and clinical trials on AD dementia or related symptoms and ASMs. Study quality was rated by the Oxford Centre for Evidence-Based Research Medicine. Results: A total of 27 studies with 1,241,796 participants were included. Data on AD risk from level IB-IIIB evidence studies showed mixed results, with some indicating an increased association with ASM use [OR = 1.05–1.16, 95% CI: 1.01–1.24]. Studies on AD-related symptoms from level IB-IV evidence also showed mixed results. Only three North American studies explicitly included race/ethnicity; most were conducted in European countries. Conclusions: ASM use may be modestly associated with an increased risk of AD among the older adult population, but current data are inconclusive. The association of ASMs on AD-related symptoms varied. Future studies should emphasize reporting sociodemographic data and include diverse cohorts to enhance the applicability of findings.
- Open Access
- 28 April 2020
- Published by MDPI AG in Geriatrics
- Vol. 5 (2) , 27
A Systematic Review Examining Associations between Cardiovascular Conditions and Driving Outcomes among Older Drivers
There is a vast literature on stroke as a cardiovascular disease and driving outcomes, however little is known about other cardiovascular conditions and driving. The purpose of this review is to examine the literature for studies assessing the effect of non-stroke, vascular conditions on daily driving, reported crash risk and driving decline in older adult drivers as captured by naturalistic methodologies. A systematic review of Embase, Ovid and Scopus Plus examined articles on driving and vascular conditions among older adults. A search yielded 443 articles and, following two screenings, no articles remained that focused on non-stroke, vascular conditions and naturalistic driving. As a result, this review examined non-stroke, vascular conditions in nine driving studies of older adults that used road testing, driving simulators and self-report measures. These studies fell into three categories—heart failure, vascular dementia and white matter hyperintensities/leukoaraiosis. The combined findings of the studies suggest that heart failure, vascular dementia and white matter hyperintensities (WMH) negatively impact driving performance and contribute to driving cessation among older adults. Future research should examine cardiovascular risk factors like hypertension, hypercholesterolemia, myocardial infraction or atherosclerosis using naturalistic driving measurement, as well as traditional measures, in order to more fully characterize how these conditions impact older adult driving.
- 28 April 2020
- Published by MDPI AG in Geriatrics
- Vol. 5 (2) , 27
Open AccessA Systematic Review Examining Associations between Cardiovascular Conditions and Driving Outcomes among Older Drivers
There is a vast literature on stroke as a cardiovascular disease and driving outcomes, however little is known about other cardiovascular conditions and driving. The purpose of this review is to examine the literature for studies assessing the effect of non-stroke, vascular conditions on daily driving, reported crash risk and driving decline in older adult drivers as captured by naturalistic methodologies. A systematic review of Embase, Ovid and Scopus Plus examined articles on driving and vascular conditions among older adults. A search yielded 443 articles and, following two screenings, no articles remained that focused on non-stroke, vascular conditions and naturalistic driving. As a result, this review examined non-stroke, vascular conditions in nine driving studies of older adults that used road testing, driving simulators and self-report measures. These studies fell into three categories—heart failure, vascular dementia and white matter hyperintensities/leukoaraiosis. The combined findings of the studies suggest that heart failure, vascular dementia and white matter hyperintensities (WMH) negatively impact driving performance and contribute to driving cessation among older adults. Future research should examine cardiovascular risk factors like hypertension, hypercholesterolemia, myocardial infraction or atherosclerosis using naturalistic driving measurement, as well as traditional measures, in order to more fully characterize how these conditions impact older adult driving.